OR WAIT null SECS
Aenova Group and Microcaps are partnering to enable new customized formulations for product development and life cycle management solutions.
The Aenova Group, a global contract manufacturing and development organization, and Microcaps, a Swiss biotechnology start-up specializing in microencapsulation technology, announced a strategic partnership on Oct. 21, 2022. The aim of the partnership is to accelerate and improve the development and production of pharmaceuticals, food supplements, and other products.
According to a company press release, Microcaps will use its patented microencapsulation technology platform to enable customized formulations such as release, protective coating and texture, etc. This is intended to allow Aenova to offer a broader range of new product development and life cycle management solutions for micro and convention capsule formulations, such as enhanced taste masking, controlled release, targeted release, increased bioavailability, and improved active pharmaceutical ingredient stability.
"In our now launched partnership, the whole is clearly more than the sum of its parts, because the portfolio and the experience and knowledge of the individual companies complement each other perfectly in order to be able to offer even better added value for our customers in the pharmaceutical as well as the food industry even faster,” said Jan Kengelbach, CEO, Aenova Group, and Michael Hagander, co-founder and co-CEO, Microcaps, in a joint statement in the release.
More details about the partnership will be discussed at this year’s CPHI conference November 1 to 3, 2022 in Frankfurt/Main at the Aenova in Hall 9, booth 90J60.
Source: Aenova Group